Cargando…
Validating a breast cancer score in Spanish women. The MCC-Spain study
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiabl...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813036/ https://www.ncbi.nlm.nih.gov/pubmed/29445177 http://dx.doi.org/10.1038/s41598-018-20832-0 |
_version_ | 1783300107982077952 |
---|---|
author | Dierssen-Sotos, Trinidad Gómez-Acebo, Inés Palazuelos, Camilo Fernández-Navarro, Pablo Altzibar, Jone M González-Donquiles, Carmen Ardanaz, Eva Bustamante, Mariona Alonso-Molero, Jessica Vidal, Carmen Bayo-Calero, Juan Tardón, Adonina Salas, Dolores Marcos-Gragera, Rafael Moreno, Víctor Rodriguez-Cundin, Paz Castaño-Vinyals, Gemma Ederra, María Vilorio-Marqués, Laura Amiano, Pilar Pérez-Gómez, Beatriz Aragonés, Nuria Kogevinas, Manolis Pollán, Marina Llorca, Javier |
author_facet | Dierssen-Sotos, Trinidad Gómez-Acebo, Inés Palazuelos, Camilo Fernández-Navarro, Pablo Altzibar, Jone M González-Donquiles, Carmen Ardanaz, Eva Bustamante, Mariona Alonso-Molero, Jessica Vidal, Carmen Bayo-Calero, Juan Tardón, Adonina Salas, Dolores Marcos-Gragera, Rafael Moreno, Víctor Rodriguez-Cundin, Paz Castaño-Vinyals, Gemma Ederra, María Vilorio-Marqués, Laura Amiano, Pilar Pérez-Gómez, Beatriz Aragonés, Nuria Kogevinas, Manolis Pollán, Marina Llorca, Javier |
author_sort | Dierssen-Sotos, Trinidad |
collection | PubMed |
description | A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations. |
format | Online Article Text |
id | pubmed-5813036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58130362018-02-21 Validating a breast cancer score in Spanish women. The MCC-Spain study Dierssen-Sotos, Trinidad Gómez-Acebo, Inés Palazuelos, Camilo Fernández-Navarro, Pablo Altzibar, Jone M González-Donquiles, Carmen Ardanaz, Eva Bustamante, Mariona Alonso-Molero, Jessica Vidal, Carmen Bayo-Calero, Juan Tardón, Adonina Salas, Dolores Marcos-Gragera, Rafael Moreno, Víctor Rodriguez-Cundin, Paz Castaño-Vinyals, Gemma Ederra, María Vilorio-Marqués, Laura Amiano, Pilar Pérez-Gómez, Beatriz Aragonés, Nuria Kogevinas, Manolis Pollán, Marina Llorca, Javier Sci Rep Article A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations. Nature Publishing Group UK 2018-02-14 /pmc/articles/PMC5813036/ /pubmed/29445177 http://dx.doi.org/10.1038/s41598-018-20832-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Dierssen-Sotos, Trinidad Gómez-Acebo, Inés Palazuelos, Camilo Fernández-Navarro, Pablo Altzibar, Jone M González-Donquiles, Carmen Ardanaz, Eva Bustamante, Mariona Alonso-Molero, Jessica Vidal, Carmen Bayo-Calero, Juan Tardón, Adonina Salas, Dolores Marcos-Gragera, Rafael Moreno, Víctor Rodriguez-Cundin, Paz Castaño-Vinyals, Gemma Ederra, María Vilorio-Marqués, Laura Amiano, Pilar Pérez-Gómez, Beatriz Aragonés, Nuria Kogevinas, Manolis Pollán, Marina Llorca, Javier Validating a breast cancer score in Spanish women. The MCC-Spain study |
title | Validating a breast cancer score in Spanish women. The MCC-Spain study |
title_full | Validating a breast cancer score in Spanish women. The MCC-Spain study |
title_fullStr | Validating a breast cancer score in Spanish women. The MCC-Spain study |
title_full_unstemmed | Validating a breast cancer score in Spanish women. The MCC-Spain study |
title_short | Validating a breast cancer score in Spanish women. The MCC-Spain study |
title_sort | validating a breast cancer score in spanish women. the mcc-spain study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813036/ https://www.ncbi.nlm.nih.gov/pubmed/29445177 http://dx.doi.org/10.1038/s41598-018-20832-0 |
work_keys_str_mv | AT dierssensotostrinidad validatingabreastcancerscoreinspanishwomenthemccspainstudy AT gomezaceboines validatingabreastcancerscoreinspanishwomenthemccspainstudy AT palazueloscamilo validatingabreastcancerscoreinspanishwomenthemccspainstudy AT fernandeznavarropablo validatingabreastcancerscoreinspanishwomenthemccspainstudy AT altzibarjonem validatingabreastcancerscoreinspanishwomenthemccspainstudy AT gonzalezdonquilescarmen validatingabreastcancerscoreinspanishwomenthemccspainstudy AT ardanazeva validatingabreastcancerscoreinspanishwomenthemccspainstudy AT bustamantemariona validatingabreastcancerscoreinspanishwomenthemccspainstudy AT alonsomolerojessica validatingabreastcancerscoreinspanishwomenthemccspainstudy AT vidalcarmen validatingabreastcancerscoreinspanishwomenthemccspainstudy AT bayocalerojuan validatingabreastcancerscoreinspanishwomenthemccspainstudy AT tardonadonina validatingabreastcancerscoreinspanishwomenthemccspainstudy AT salasdolores validatingabreastcancerscoreinspanishwomenthemccspainstudy AT marcosgragerarafael validatingabreastcancerscoreinspanishwomenthemccspainstudy AT morenovictor validatingabreastcancerscoreinspanishwomenthemccspainstudy AT rodriguezcundinpaz validatingabreastcancerscoreinspanishwomenthemccspainstudy AT castanovinyalsgemma validatingabreastcancerscoreinspanishwomenthemccspainstudy AT ederramaria validatingabreastcancerscoreinspanishwomenthemccspainstudy AT viloriomarqueslaura validatingabreastcancerscoreinspanishwomenthemccspainstudy AT amianopilar validatingabreastcancerscoreinspanishwomenthemccspainstudy AT perezgomezbeatriz validatingabreastcancerscoreinspanishwomenthemccspainstudy AT aragonesnuria validatingabreastcancerscoreinspanishwomenthemccspainstudy AT kogevinasmanolis validatingabreastcancerscoreinspanishwomenthemccspainstudy AT pollanmarina validatingabreastcancerscoreinspanishwomenthemccspainstudy AT llorcajavier validatingabreastcancerscoreinspanishwomenthemccspainstudy |